Starpharma today confirmed Mr Peter Bartels AO will retire as Chairman as part of a planned succession. As announced in November 2013, Mr Rob Thomas AM will succeed Mr Bartels as Chairman, effective today.

In this issue:

› VivaGel^® BV prevention of recurrence: start of phase 3 trials close

› R&D tax incentive cash received

› DEP™ docetaxel trial progressing well

› VivaGel^®-coated condom: preparing for launch

› VivaGel^® BV symptomatic relief product: commercial and regulatory progress

› Strong results for dendrimer enhanced agrochemicals

Download: Shareholder Update: June 2014 ( pdf file, 2MB)

Starpharma today provided an update on the progress of its clinical trial programs, which include the Phase 1 DEP™ docetaxel trial and the Phase 3 pivotal trials of VivaGel^® for prevention of recurrent bacterial vaginosis (BV).

 Highlights:

 Phase 1 DEP™ docetaxel trial:

- Ethics approval at 3 sites in Australia

- Enrolling patients; a number having received multiple cycles of therapy

- No evidence of neutropenia

 Phase 3 VivaGel^® for prevention of recurrent BV:

- Agreement with EMA and FDA on study design

- First ethics approval obtained

- Quintiles CRO engaged

- Nearing commencement